Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORX750 Long-term Extension in Narcolepsy and Idiopathic Hypersomnia
NCT07096674Phase 2Recruiting
- Sponsor
- Centessa Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of cleminorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), sponsored by Centessa Pharmaceuticals. Started Aug 2025; status: recruiting.
02
Drugs
cleminorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT07096674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096674.